부산대학교 도서관

Background: Atopic dermatitis (AD) is a chronic inflammatory disease. Recently, dupilumab was approved for moderate‐to‐severe AD. D‐OCT is a noninvasive tool for the characterization of skin diseases. Objective: To describe the changes observed with D‐OCT in lesional and clinically healthy skin of patients with refractory severe AD under dupilumab treatment. Methods: We analyzed AD lesions and healthy skin by D‐OCT. Clinical scores of AD severity were assessed at baseline (T0) and after 1 and 3 months of treatment (T1, T2). Descriptive statistics, chi‐square test, and t test were used to compare the analyzed parameters over time and between AD lesions and clinically healthy skin. Results: At baseline, average EASI was 45.7. During the follow‐up, EASI75 and EASI90 were achieved in 57% and 36% of patients at T1 and 100% and 86% of patients at T2, respectively. Lesional skin D‐OCT parameters related to epidermal remodeling and inflammation evidenced a significant improvement after 1 month of treatment. In clinically healthy skin, D‐OCT parameters improved significantly after 3 months of treatment, especially for collagen remodeling and inflammation. Conclusion: The study demonstrates that the clinical improvement of severe AD patients under dupilumab treatment is correlated with specific D‐OCT changes of patients' lesional and clinically healthy skin. [ABSTRACT FROM AUTHOR]